The Division of Community, Recovery, Research and Training conducts research into the genetic and biological underpinnings of psychotic disorders. Neuroimaging studies are carried out that examine the way in which the brain works and the areas of the brain activated by different symptoms or cognitive tests. This research may help us to understand how these illnesses develop and to identify more effective treatment strategies.
In addition, we study and develop new and innovative pharmacological and psychosocial treatments to improve symptoms and enhance the quality of life for individuals with these disorders. Treating the positive symptoms of schizophrenia (including hallucinations, false beliefs, and suspiciousness) addresses only one group of symptoms for individuals with schizophrenia. New treatments aimed at bypassing problems with information processing and memory and reducing negative symptoms (problems with motivation and social withdrawal) are being developed and studied by researchers in the Division of Community Recovery, Research and Trainings. Developing interventions for the many issues faced by individuals with these disorders is important in improving outcomes. Division researchers study how best to implement evidence-based practices in the pharmacological treatment of schizophrenia and related disorders.
Individuals who are dealing with substance abuse issues and who are ages 18-65. Currently, there are clinical trials being ran for those who actively use crack cocain and marijuana, and have interest in stopping.
No fees, as participation in the clinical trials is completely voluntary.